30
Views
4
CrossRef citations to date
0
Altmetric
Case Report

Atypical severe central serous chorioretinopathy in a patient with systemic lupus erythematosus improved with a rapid reduction in glucocorticoid

, , , , , , , & show all
Pages 172-174 | Received 17 Jan 2012, Accepted 05 Mar 2012, Published online: 02 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Lauren Y. Chan, Robert S. Adam & David N. Adam. (2016) Localized topical steroid use and central serous retinopathy. Journal of Dermatological Treatment 27:5, pages 425-426.
Read now

Articles from other publishers (3)

Gabriel Lipsker, Mathieu Wurtz & Dan Lipsker. (2022) Topical steroid‐induced visual disturbances related to central serous chorioretinopathy. A potentially serious complication of dermocorticoids. Journal of the European Academy of Dermatology and Venereology 37:5.
Crossref
Qingqing Rao, Ming Ku & Qijun Wan. (2023) A case report of systemic lupus erythematosus combined with central serous chorioretinopathy treated with glucocorticoids. Journal of International Medical Research 51:3, pages 030006052311637.
Crossref
Diogo Hipolito-Fernandes, Maria Elisa Luís, Rita Flores & Rita Anjos. (2021) Non-central serous chorioretinopathy in a patient with systemic lupus erythematosus and hydroxychloroquine retinopathy. BMJ Case Reports 14:1, pages e237243.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.